First-in-Human trial tests engineered immune cells to fight tough melanoma
NCT ID NCT06660420
Summary
This is an early-stage study to find a safe and effective dose of a new cell therapy for people with advanced melanoma that has come back or stopped responding to standard treatments. Doctors will give participants immune cells (NK cells) that have been specially engineered in a lab to target a protein called PRAME found on melanoma cells. The main goals are to see how well the treatment is tolerated and if it can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.